These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 28919633)

  • 1. Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains.
    Sidana S; Tandon N; Dispenzieri A; Gertz MA; Buadi FK; Lacy MQ; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Kapoor P; Kyle RA; Leung N; Go RS; Lust JA; Russell SJ; Zeldenrust SR; Rajkumar SV; Kumar SK
    Leukemia; 2018 Mar; 32(3):729-735. PubMed ID: 28919633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical presentation and prognosis of light-chain amyloidosis patients with unmeasurable free light-chain levels.
    Qiu Y; Zhang CL; Shen KN; Su W; Feng J; Zhang L; Cao XX; Li J
    Ann Hematol; 2018 Dec; 97(12):2465-2470. PubMed ID: 30056579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome.
    Milani P; Basset M; Russo F; Foli A; Merlini G; Palladini G
    Blood; 2017 Aug; 130(5):625-631. PubMed ID: 28546143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis.
    Dittrich T; Bochtler T; Kimmich C; Becker N; Jauch A; Goldschmidt H; Ho AD; Hegenbart U; Schönland SO
    Blood; 2017 Aug; 130(5):632-642. PubMed ID: 28550043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of patients with AL amyloidosis and low serum free light chain levels at diagnosis.
    Nguyen VP; Rosenberg A; Mendelson LM; Comenzo RL; Varga C; Sanchorawala V
    Amyloid; 2018 Sep; 25(3):156-159. PubMed ID: 30032640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of light chain isotype on clinical features and outcomes in systemic AL amyloidosis.
    Hopson MB; Bhutani D; Sarkaria S; Maurer MS; Griffin JM; Mapara M; Lentzsch S; Chakraborty R
    Leuk Lymphoma; 2022 Sep; 63(9):2109-2113. PubMed ID: 35465769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib.
    Manwani R; Cohen O; Sharpley F; Mahmood S; Sachchithanantham S; Foard D; Lachmann HJ; Quarta C; Fontana M; Gillmore JD; Whelan C; Hawkins PN; Wechalekar AD
    Blood; 2019 Dec; 134(25):2271-2280. PubMed ID: 31578202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posttreatment dFLC less than 10 mg/L predicts superior organ response and longer time to next treatment in newly diagnosed light-chain amyloidosis patients treated with bortezomib.
    Shen KN; Miao HL; Zhang CL; Feng J; Zhang L; Cao XX; Zhou DB; Wei S; Li J
    Leuk Lymphoma; 2021 Apr; 62(4):874-882. PubMed ID: 33215569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. At least partial hematological response after first cycle of treatment predicts organ response and long-term survival for patients with AL amyloidosis receiving bortezomib-based treatment.
    Shen KN; Feng J; Huang XF; Zhang CL; Zhang CL; Cao XX; Zhang L; Zhou DB; Li J
    Ann Hematol; 2017 Dec; 96(12):2089-2094. PubMed ID: 28956112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis.
    Sarosiek S; Zheng L; Sloan JM; Quillen K; Brauneis D; Sanchorawala V
    Blood Cancer J; 2020 Sep; 10(8):88. PubMed ID: 32873776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis.
    Sachchithanantham S; Berlanga O; Alvi A; Mahmood SA; Lachmann HJ; Gillmore JD; Hawkins PN; Harding S; Wechalekar AD
    Br J Haematol; 2017 Nov; 179(4):575-585. PubMed ID: 28990174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The prognostic value of baseline serum free light chain in immunoglobulin light-chain cardiac amyloidosis].
    Wang LM; Wang TT; Tian Y; Zhao L; Yang XC; Chen WM
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jan; 41(1):47-53. PubMed ID: 32023754
    [No Abstract]   [Full Text] [Related]  

  • 13. Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy.
    Milani P; Basset M; Nuvolone M; Benigna F; Rodigari L; Lavatelli F; Foli A; Merlini G; Palladini G
    Blood Cancer J; 2020 Sep; 10(8):90. PubMed ID: 32873771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical presentation and prognosis in patients with light-chain amyloidosis with an ultra-high level of serum free light-chain].
    Miao HL; Shen KN; Su W; Zhang L; Cao XX; Zhou DB; Li J
    Zhonghua Xue Ye Xue Za Zhi; 2021 Mar; 42(3):199-204. PubMed ID: 33910304
    [No Abstract]   [Full Text] [Related]  

  • 15. [The prognostic value of baseline serum free light chain in cardiac amyloidosis].
    Zhao L; Tian Z; Fang Q
    Zhonghua Nei Ke Za Zhi; 2016 Mar; 55(3):186-90. PubMed ID: 26926369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up.
    Basset M; Kimmich CR; Schreck N; Krzykalla J; Dittrich T; Veelken K; Goldschmidt H; Seckinger A; Hose D; Jauch A; Müller-Tidow C; Benner A; Hegenbart U; Schönland SO
    Br J Haematol; 2021 Oct; 195(2):230-243. PubMed ID: 34341985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features.
    Kumar S; Dispenzieri A; Katzmann JA; Larson DR; Colby CL; Lacy MQ; Hayman SR; Buadi FK; Leung N; Zeldenrust SR; Ramirez-Alvarado M; Clark RJ; Kyle RA; Rajkumar SV; Gertz MA
    Blood; 2010 Dec; 116(24):5126-9. PubMed ID: 20798235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis.
    Sidana S; Tandon N; Gertz MA; Dispenzieri A; Ramirez-Alvarado M; Murray DL; Kourelis TV; Buadi FK; Kapoor P; Gonsalves W; Warsame R; Lacy MQ; Kyle RA; Rajkumar SV; Kumar SK; Leung N
    Br J Haematol; 2019 May; 185(4):701-707. PubMed ID: 30836444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio.
    Muchtar E; Gertz MA; Lacy MQ; Leung N; Buadi FK; Dingli D; Hayman SR; Go RS; Kapoor P; Gonsalves W; Kourelis TV; Warsame R; Hwa YL; Fonder A; Hobbs M; Russell S; Lust JA; Siddiqui M; Rajkumar SV; Kyle RA; Kumar SK; Dispenzieri A
    Am J Hematol; 2020 Nov; 95(11):1280-1287. PubMed ID: 32681737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum monoclonal immunoglobulin light-chain detection differs between immunofixation electrophoresis methods in patients with AL amyloidosis.
    Kawano Y; Nishimura N; Yasunaga JI
    Int J Hematol; 2024 Aug; 120(2):212-216. PubMed ID: 38739302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.